Agodoa, Lawrence and Alanis, Alfonso J. and Alexander-Bridges, Maria and Doan, Loretta L. and Fleming, G. Alexander and Getz, Ken and Gibbs, Brian K. and Prothrow-Stith, Deborah
Abstract
Our goal is to ensure that clinical research supporting 1) the safety and efficacy of products for labeling purposes and 2) the validity of biomarkers commonly used to assess risk and to design therapeutic strategies is based on data sufficient for statistical power and derived from diverse subpopulations. It is widely recognized that data supporting therapeutic options for women and minorities have been deficient because these groups were not previously included in clinical trials. Although the combined efforts of Congress, the Office of Women’s Health at the Food and Drug Administration (FDA), and the Office of Research on Women’s Health…
| Export/Citation: | EndNote | BibTeX | Dublin Core | ASCII (Chicago style) | HTML Citation | OpenURL | Reference Manager |
| Social Networking: |
| Item Type: | Report Document or other Monograph (Discussion Paper) |
|---|---|
| Additional Information: | This article is available at the publisher’s Web site. Access to the full text is subject to the publisher’s access restrictions. |
| Subjects: | Health > Health Equity Health > Pharmacotherapy Health > Policy Research Research > Genetics and Race |
| Related URLs: | |
| Depositing User: | Users 141 not found. |
| Date Deposited: | 07 Sep 2011 10:50 |
| Last Modified: | 07 Sep 2011 10:50 |
| Link to this item (URI): | http://health-equity.pitt.edu/id/eprint/3209 |
Actions (login required)
| View Item |
![[feed]](http://health-equity.pitt.edu/images/feed-icon-32x32.png){kind=icon}